Kite Pharma: latest news - GoINPHARMA
Wednesday, 12 December 2018 - 0:26

Kite Pharma

Biotech sector ensures highest premium among M&A transactions

Analysts from investment bank Bryan, Garnier & Co have issued a report analyzing as many as 1,040 M&A transactions announced over the first 9 months of the year and performed in the Healthcare/Pharma sector. 132 out of the 1,040 acquired…

FDA approves Yescarta, Kite/Gilead’s CAR-T therapy

Kite, part of Gilead group, has announced that FDA has approved Yescarta (axicabtagene ciloleucel), a CAR-T (chimeric antigen receptor T cell) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines…

An analysis of Gilead

This month has been extraordinary for California-based biotech Gilead, which has reached its peak by acquiring Kite for $11bn. The deal has put the company in a favorable position in the CAR-T cell therapies business. The acquisition has met with…

Further details on $12bn takeover of Kite Pharma by Gilead

Gilead acquired California-based Kite Pharma for $11.9bn, that is a 29% premium over last Friday’s closing price and 66% over the company’s valuation 12 months ago. The acquisition makes Gilead the leader in CAR-T (Chimeric Antigen Receptor T) cell therapies,…

Gilead makes widely-anticipated move – Kite acquired for $11.9bn

Gilead announced today, before Wall Street opened, that it has acquired the biotech Kite Pharma Inc. for $11.9bn, corresponding to valuing the company at $180 per share, with a 29% premium to Friday’s closing price. Gilead’s investors had been urging…

Excellent clinical results for Kite, shares notch record growth: +12%

Kite Pharma announced to the Annual Meeting of American Society of Hematology the preliminary results of its ZUMA-1 clinical trial, designed to assess axicabtagene ciloleucel (KTE-C19) in patients with non-Hodgkin lymphoma. The data were positive: indeed, they demonstrated that 82%…

A bright future for Juno Therapeutics

Although Juno Therapeutics (Seattle) still has not a single drug on the market, it has recently reached over $2.8bn value, thanks to developing the CAR-T therapy, a modern immunotherapy for cancer treatment. Juno also benefits from a 10-year cooperation with…

Kite’s CAR-T therapy development likely to speed up

Kite Pharma announced at an investor day presentation positive results from an interim analysis of its CAR-T product candidate—KTE-C19—suggesting it will be possible to submit the application for the treatment approval in a short time. In particular, ZUMA-1 Phase II…